Shanghai Fosun Pharmaceutical Group Co. Ltd.
Division of Fosun International Ltd.
www.fosunpharma.com/en
Latest From Shanghai Fosun Pharmaceutical Group Co. Ltd.
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.
Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
Company Information
- Industry
- Distributors
- In Vitro Diagnostics
- Medical Devices
-
Pharmaceuticals
- Vaccines
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
China
-
China
-
Asia
- Parent & Subsidiaries
-
Fosun International Ltd.
-
Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Breas Medical AB
- Chongqing Fochon Pharmaceutical Research Co. Ltd.
- Hunan Dongting Pharmaceutical Co. Ltd.
- Jinzhou Ahon Pharmaceutical Co Ltd.
- Shanghai Chemo Wanbang Biopharma Co. Ltd.
- Shanghai Fosun Long March Medical Science Co. Ltd.
- Suzhou Erye Pharmaceutical Co. Ltd.
- Wanbang Biopharmaceuticals Ltd.
-
Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Senior Management
-
Wu Yifang, Pres. & CEO
Guan Xiaohui, SVP, CFO
Shao Ying, VP, Dir, R&D - Contact Info
-
Shanghai Fosun Pharmaceutical Group Co. Ltd.
Phone: (86) 21 33987000
1289 Yishan Rd.
Bldg. A
Shanghai , 200233
China
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice